Featured Posts

Checkpoint inhibitor therapy more economical, safe than CAR T cells in pediatric leukemia

Novel advances in the use of checkpoint inhibitors – such as an anti-PD1 or anti-PDL1 – to treat pediatric leukemia may result in the ability to eliminate the use of CAR T-cell therapy in that patient population in the future, according to Donald Durden, MD, PhD, vice chair for research at UC San Diego’s Department of Pediatrics and associate director for pediatric oncology at the Moores UCSD Cancer Center.

Read more here: http://www.healio.com/hematology-oncology/leukemia/news/online/%7Be0935e2e-d5ed-4299-a6eb-4a7bfa4ea252%7D/checkpoint-inhibitor-therapy-more-economical-safe-than-car-t-cells-in-pediatric-leukemia

Posts Are Coming Soon
Stay tuned...
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square

Email us:

info@opacc.org

A program of OPACC

Call us:

Toll-free: 1-888-290-5496

Local:         705-828-7965

Mail us: 

524 Bayfield Street North
P.O. Box 20005
Barrie, ON L4M 5E9
Canada

 

Subscribe for Updates (if you are the parent of a child with cancer, please fill out the Membership form instead)